Neuroimaging and End Stage Renal Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

192 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Brain impairment is one of the common complications of end-stage renal disease (ESRD). The patients always present with various cerebrovascular diseases, cognitive impairment and sensorimotor abnormalities, with morbidity over 40%. However, the risk factors and the neural mechanisms of brain injury in ESRD is still unclear. Identifying the risk factors and finding objective and reliable biomarkers of brain impairment in the process of ESRD is an important clinical problem. At the same time, to find the neural mechanisms of brain damage in ESRD is a serious scientific problem. Neuroimaging techniques based on multi-modal magnetic resonance image (MRI) can detect the structural and functional brain abnormalities objectively and sensitively, especially for those without obvious clinical symptoms. Through the deep analysis of brain MRI data, it is helpful for studying the neural mechanisms of brain damage in ESRD in the perspective from brain science. In addition, the accumulation of uremic toxins is supposed to play an essential role in the brain impairment of ESRD. The metabolomics is a useful method in detecting the uremic toxins with different molecular weights. In this study, the investigators will collect the brain MRI, serum metabolomics and cognitive assessment data before the dialysis initiation, and then will make prospective longitudinal observation of changes of brain impairment during the dialysis. Thus, combining analysis of neuroimaging and metabolomics will provide more information for finding the risk factors and imaging diagnostic markers of brain impairment in ESRD. It will also helpful for explaining the underlying mechanisms of brain impairment in ESRD, providing an objective basis for clinical diagnosis and prediction of the prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy

NCT06245707

Mild Cognitive Impairment Idiopathic Membranous Nephropathy

UNKNOWN NA

Association Between Cerebral Blood Flow Change and Cognitive Function in Hemodialysis Patients

NCT05555836

Hemodialysis Cerebral Blood Flow Cognitive Function +1 more

UNKNOWN

Changes of Cognitive Function and Brain Magnetic Resonance in Maintenance Hemodialysis Patients With Diabetes Mellitus

NCT05953818

Maintenance Hemodialysis

UNKNOWN

Assessment of Renal Function by Multiparametric MRI

NCT06407375

Renal Impairment

COMPLETED EARLY_PHASE1

Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease

NCT06925178

Cerebrovascular Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESRD group

magnetic resonance image (MRI)

Intervention Type DEVICE

serum metabolomics

Control group

magnetic resonance image (MRI)

Intervention Type DEVICE

serum metabolomics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

magnetic resonance image (MRI)

serum metabolomics

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

serum

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis with end stage renal disease before dialysis initiation
* Chronic renal failure
* Chronic renal failure
* 18-55 years old
* Right handedness

Exclusion Criteria

* Concurrent severe infection
* With other severe diseases
* History of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc.
* History of alcohol dependence and drug abuse
* History of brain operation
* Loss of vision or hearing
* Psychotropic medication in three months
* Contraindication of MRI examination, such as metal implants and claustrophobia, and other reasons that cannot cooperate with MRI examination
* Cerebrovascular diseases which can be detected from conventional MR images, including the size of cerebral hemorrhage over 10 mm, infarction over 20 mm, subarachnoid hemorrhage, subdural hemorrhage and extradural hemorrhage.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes